NEW YORK (TheStreet) --Shares of Aerie Pharmaceuticals (AERI) - Get Report were surging by 56.34% to $33.03 on Thursday morning, following reports that the company's glaucoma drug Roclatan has met the key endpoint in a pivotal phase three study.

"These huge gains today have reversed the year-to-date losses on the stock on yesterday's close. In fact, this stock is now up 40% year-to-date. Probably not pleasing news to the bears out there," Bloomberg TV's Abigail Doolittle reported on this morning's "Bloomberg GO."

Doolittle noted that there is a short interest in the stock at of about 18%.

Aerie Pharmaceuticals is an Irvine, CA-based drug manufacturing company focusing on the discovery and development of treatments for glaucoma, and other eye diseases.

Image placeholder title